- Home
- DECK vs NBIX Comparison
DECK vs NBIX Comparison
Compare DECK & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DECK
- NBIX
- Stock Information
- Founded
- DECK 1973
- NBIX 1992
- Country
- DECK United States
- NBIX United States
- Employees
- DECK N/A
- NBIX N/A
- Industry
- DECK Shoe Manufacturing
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DECK Consumer Discretionary
- NBIX Health Care
- Exchange
- DECK Nasdaq
- NBIX Nasdaq
- Market Cap
- DECK 14.1B
- NBIX 14.4B
- IPO Year
- DECK 1993
- NBIX 1996
- Fundamental
- Price
- DECK $80.19
- NBIX $152.99
- Analyst Decision
- DECK Buy
- NBIX Strong Buy
- Analyst Count
- DECK 21
- NBIX 18
- Target Price
- DECK $122.16
- NBIX $172.06
- AVG Volume (30 Days)
- DECK 5.4M
- NBIX 884.0K
- Earning Date
- DECK 10-23-2025
- NBIX 10-28-2025
- Dividend Yield
- DECK N/A
- NBIX N/A
- EPS Growth
- DECK 18.83
- NBIX 12.44
- EPS
- DECK 6.75
- NBIX 4.19
- Revenue
- DECK $5,244,323,000.00
- NBIX $2,682,700,000.00
- Revenue This Year
- DECK $11.56
- NBIX $23.68
- Revenue Next Year
- DECK $7.95
- NBIX $18.02
- P/E Ratio
- DECK $11.78
- NBIX $34.16
- Revenue Growth
- DECK 12.62
- NBIX 19.61
- 52 Week Low
- DECK $78.98
- NBIX $84.23
- 52 Week High
- DECK $223.98
- NBIX $154.61
- Technical
- Relative Strength Index (RSI)
- DECK 28.62
- NBIX 65.43
- Support Level
- DECK $78.98
- NBIX $133.62
- Resistance Level
- DECK $104.08
- NBIX $144.97
- Average True Range (ATR)
- DECK 2.81
- NBIX 4.32
- MACD
- DECK -1.24
- NBIX 0.53
- Stochastic Oscillator
- DECK 4.17
- NBIX 88.91
About DECK Deckers Outdoor Corporation
Founded in 1973, California-based Deckers designs and sells casual and performance footwear, apparel, and accessories. In fiscal 2025, Ugg and Hoka accounted for 51% and 45% of total sales, respectively. The firm also markets niche brands Teva and Ahnu. Deckers produces most of its sales through wholesale partnerships but also operates e-commerce in more than 50 countries and about 180 company-operated stores. It generated 64% of its fiscal 2025 sales in the United States.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.